Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients

Managed Care

Volumn 19, Issue 5, 2010, Pages 40-47

  Gibson, Teresa B ^a   Jing, Yonghua ^b   Kim, Edward ^b   Bagalman, Erin ^a   Wang, Sara ^a   Whitehead, Richard ^c   Tran, Quynh Van ^c   Doshi, Jalpa A ^d  

^a Thompson Reuters (Healthcare) Inc   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; COST; ECONOMICS; FEMALE; HEALTH INSURANCE; HUMAN; INSURANCE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COST SHARING; FEMALE; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 78149308433     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (27)

1. Ashcraft ML, Fries BE, Nerenz DR, et al: A psychiatric patient classification system. An alternative to diagnosis-related groups. Med Care. 1989;27:543.
2. Chernew ME, Gibson TB, Yu-Isenberg K: Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Int Med. 2008;23(8):1131-1136.
3. Chernew M, Gibson TB: Cost sharing and HEDIS performance. Med Care Res Rev. 2008;65:713-28.
4. Choudhry NK, Shrank WH, Levin RL, et al: Measuring concurrent adherence to multiple related medications. Am J Man Care. 2009;15:457-464.
5. Cutler A, Ball S, Stahl S: Dosing atypical antipsychotics. CNS Spectrums: Intern J of Neuropsych Med. 2008;13(5 Suppl 9):1-16.
6. Dezii CM: Persistence with drug therapy: A practical approach using administrative claims data.Man Care. 2001;10:42-45.
7. Fendrick AM, Smith DG, Chernew ME, et al: A benefit-based copay for prescription drugs: Patient contribution based on total benefits, not drug acquisition cost. Am J Man Care. 2001;7(9):861-867.
8. Gianfrancesco FD, Sajatovic M, Rajagopalan K, et al: Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. ClinTher. 2008;30:1358-1374.
9. Gibson TB, Ozminkowski RJ, Goetzel RZ: The effects of prescripion drug cost sharing: A review of the evidence. Am J Man Care. 2005;11: 730-740.
10. Gilmer TP, Dolder CR, Lacro JP, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psych. 2004;161:692-699.
11. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing. Associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-69.
12. Hartung DM, Carlson MJ, Kraemer DF, et al. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population. Med Care. 2008;469(6):565-572.
13. Hassan M and Lage M: Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health-Sys Pharm 2009;66:358-365.
14. Joyce GF, Escarce JJ, Solomon MD, et al: Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288:1733-1739.
15. Lage MJ and Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psych. 2009;8:7.
16. Liu-Seifert H, Adams, DH, Kinon, BJ: Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled posthoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.
17. Merikangas KR, Akiskal HS, Angst J, et al: Lifetime and 12-Month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psych. 2007;64: 543-552.
18. National Institute of Mental Health: The Numbers Count: Mental Disorders in America. 2008. Retrieved July 19, 2010 from: http://www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america/index.shtml.
19. National Institute of Mental Health: Schizophrenia. 2009. Retrieved July 19, 2010 from: http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml.
20. Romano PS, Roos LL, Jollis JG: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epid. 1993;46:1075-1079.
21. Sajatovic M, Valenstein M, Blow FC, et al: Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Dis. 2006;8: 232-241.
22. Slade EP, Salkever DS, Rosenheck R, et al: Cost-sharing requirements and access to mental health care among Medicare enrollees with schizophrenia. Psych Serv. 2005;56(8):960-966.
23. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al: Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Eng J of Med. 1994; 331: 650-655.
24. Soumerai SB, Ross-Degnan D, Avorn J, et al: Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Eng J Med. 1991;325:1072-1077.
25. Valenstein M, Blow FC, Copeland LA et al: Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors. Schiz Bull. 2004;30:255-264.
26. Woltmann EM, Valenstein M, Welsh DE, et al: Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness. Psych Serv. 2007;58:864-867.
27. Zeber JE, Grazier KL, Valenstein M, et al: Effect of a medication copayment increase in veterans with schizophrenia. Am J Man Care. 2007;13(6 Pt 2):335-346.